Neoepitope-based cancer vaccines in human papillomavirus–negative head and neck squamous cell carcinoma: a review

Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) has a substantial risk of recurrence despite multimodal treatment. Mutation-derived neoepitopes provide a rationale for personalized vaccination, but their clinical relevance depends on target expression and clonality, effective antigen presentation, and access of functional T cells to malignant cells. This narrative review distinguishes direct HPV-negative HNSCC evidence from HNSCC-inclusive programs, shared-antigen comparators, target-selection technologies, and cross-tumor studies. The randomized phase I TG4050 study in 33 patients with resected HPV-negative HNSCC supports feasibility and immunogenicity; its small sample, few recurrence events, and per-protocol recurrence analysis preclude definitive efficacy conclusions. Complementary translational and cross-tumor studies inform antigen selection, vaccine delivery, and combination strategies, with uncertain transferability to HPV-negative HNSCC. We examine the separate evidentiary requirements for predicted targets, natural human leukocyte antigen (HLA) presentation, T-cell recognition, tumor-cell killing, and clinical benefit. We discuss spatial immune profiling to investigate resistance and circulating tumor DNA to monitor disease, while emphasizing that their roles in guiding vaccination remain exploratory. Future studies should define the treatment setting, evaluate whether vaccination adds benefit to contemporary standard treatment, report manufacturing attrition and time to first dose, and connect standardized immune measurements with clinical outcomes. Personalized neoepitope vaccination remains investigational in HPV-negative HNSCC, and adequately powered randomized trials are required to establish its clinical role.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1988672
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neoepitope-based cancer vaccines in human papillomavirus–negative head and neck squamous cell carcinoma: a review

O. Garrone, Michele Ghidini, Gianluca Martino Tartaglia, Nerina Denaro et al.
3 links
Frontiers in Immunology
Immunotherapy and Immune Responses
article

Neoepitope-based cancer vaccines in human papillomavirus–negative head and neck squamous cell carcinoma: a review

O. Garrone, Michele Ghidini, Gianluca Martino Tartaglia, Nerina Denaro, Alberto Paderno, Funda Göker, Aldo Bruno Giannì, Massimo Del Fabbro, Giovanna Rossi, Francesco Carlo Tartaglia, Paolo Bossi
article en

Abstract

Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) has a substantial risk of recurrence despite multimodal treatment. Mutation-derived neoepitopes provide a rationale for personalized vaccination, but their clinical relevance depends on target expression and clonality, effective antigen presentation, and access of functional T cells to malignant cells. This narrative review distinguishes direct HPV-negative HNSCC evidence from HNSCC-inclusive programs, shared-antigen comparators, target-selection technologies, and cross-tumor studies. The randomized phase I TG4050 study in 33 patients with resected HPV-negative HNSCC supports feasibility and immunogenicity; its small sample, few recurrence events, and per-protocol recurrence analysis preclude definitive efficacy conclusions. Complementary translational and cross-tumor studies inform antigen selection, vaccine delivery, and combination strategies, with uncertain transferability to HPV-negative HNSCC. We examine the separate evidentiary requirements for predicted targets, natural human leukocyte antigen (HLA) presentation, T-cell recognition, tumor-cell killing, and clinical benefit. We discuss spatial immune profiling to investigate resistance and circulating tumor DNA to monitor disease, while emphasizing that their roles in guiding vaccination remain exploratory. Future studies should define the treatment setting, evaluate whether vaccination adds benefit to contemporary standard treatment, report manufacturing attrition and time to first dose, and connect standardized immune measurements with clinical outcomes. Personalized neoepitope vaccination remains investigational in HPV-negative HNSCC, and adequately powered randomized trials are required to establish its clinical role.

Frontiers in ImmunologyVol. 17
University of Insubria (IT), University of Parma (IT), Humanitas University (IT), Istanbul Aydın University (TR), University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), IRCCS Humanitas Research Hospital (IT), Aziende Socio Sanitarie Territoriale dei Sette Laghi (IT)
Università degli Studi di Milano, Ministero della Salute
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon